Novo Nordisk ® eared to have a well tolerated exploratory efficacy t 1 Mim8 safety characteristics N=10 Adverse events • No dose-dependency on rates, causality, type or severity of adverse events • No thromboembolic events • Three serious AEs deemed unrelated to trial product and two hypersensitivity reactions • Injection site reactions in only 1% of injections (6 events of ~600 injections given) Cohort 5 35mg QW with ≥2 bleeds n the 12 weeks Anti-Mim8 antibodies • No occurrence of anti-Mim8 antibodies detected Overall, no safety concern observed
Download PDF file